AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Original) A nucleic acid molecule comprising:

(a) a nucleic acid sequence encoding the monocyte-chemoattractant-protein-1 (MCP-1) or a protein having the biological activity of the monocyle-chemoattractant-protein-1 (MCP-1); and

(b) a 3`-DHSR comprising a nucleic acid molecule which is located 2430 bp to 3019 bp downstream of the transcriptional start site of the MCP-1 gene, or

a 3'-DHSR comprising a nucleic acid molecule which is located 1550 bp to 1749 downstream of the transcriptional start site of the MCP-1 gene, or

a 3'-DHSR comprising a nucleic acid molecule which is located 750 bp to 899 bp downstream of the transcriptional start site of the MCP-1 gene, or

a 5'-DHSR comprising a nucleic acid molecule which is located 500 bp to 251 bp upstream of the transcriptional start site of the MCP-1 gene, or

a 5'-DHSR comprising a nucleic acid molecule which is located 1300 bp to 1001 bp upstream of the transcriptional start site of the MCP-1 gene, or

a 5'-DHSR comprising a nucleic acid molecule which is located 5050 bp to 4751 bp upstream of the transcriptional start site of the MCP-1 gene, or

a S1 hypersensitive site comprising a nucleic acid molecule which is located in the 1st intron (+180 - +350) of the MCP-1 gene.

Claim 2. (Currently Amended) The nucleic acid molecule of claim 1, wherein the 3'-DHSR comprises the nucleic acid sequence from ~~pos.~~ position +2430 to +3019 as depicted in Figure 6.

Claim 3. (Currently Amended) The ~~nucleid~~ nucleic acid molecule of claim 2, wherein the 3'-DHSR comprises the nucleic acid sequence GGAAGGTTGAGTCAAGGATT.

Claim 4. (Original) The nucleic acid molecule of claim 3, wherein the 3'-DHSR comprises the nucleic acid sequence TGAGTCA.

Claim 5. (Previously Presented) The nucleic acid molecule of claim 1, wherein the hypersensitivity sequences (b) contain mutations resulting in a modified DNAse I hypersensitivity, S1 hypersensitivity and/or altered interaction with transcription factors.

Claim 6. (Original) The nucleic acid molecule of claim 5, wherein the transcription factor is AP-1, SP1, NF-IL6 or NF-kappa B.

Claim 7. (Currently Amended) A recombinant vector containing the nucleic acid ~~molecular~~ molecule of claim 1.

Claim 8. (Original) The recombinant vector of claim 7 wherein the nucleic acid molecule is operatively linked to regulatory elements allowing transcription and synthesis of a translatable RNA in prokaryotic and/or eukaryotic host cells.

Claim 9. (Previously Presented) A recombinant host cell which contains a nucleic acid molecule according to claim 1.

Claim 10. (Original) The recombinant host cell of claim 9, which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.

Claim 11. (Currently Amended) A pharmaceutical composition comprising a compound which is capable of regulating the expression of the MCP-1 gene by directly or indirectly interacting with the nucleic acid ~~sequence~~ molecule (b) of claim 1.

Claim 12. (Original) The pharmaceutical composition of claim 11, wherein the compound is a protein capable of interacting with a transcription factor, in particular AP-1, or a nucleic acid molecule encoding said protein.

Claim 13. (Original) The pharmaceutical composition of claim 12, wherein the compound is *jun, fra-1, ATF-2, jab-1, fra-2* or a mixture thereof.

Claim 14. (Previously Presented) A method for the treatment of atherosclerosis or cancer comprising administering an effective amount of the nucleic acid molecule of claim 1 to a patient in need of such treatment.

Claim 15. (Previously Presented) The method according to claim 14, wherein the cancer is a cervical carcinoma.